Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00248625 · ClinicalTrials.gov registry record · Phase 3

N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure

A Phase 3 study, sponsored by University of Pittsburgh.

Completed
Registry status
Phase 3
Development phase
184
Enrollment target

NCT00248625: Completed Phase 3 study, sponsored by University of Pittsburgh.

NCT00248625 is a Phase 3 study that has completed, run by University of Pittsburgh. The registered enrollment target is 184 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00248625, a Phase 3 study, has completed, sponsored by University of Pittsburgh.

COMPLETED
Registry status
Phase 3
Development phase
184 participants
Enrollment target

Study Summary

We have completed patient enrollment in the the double blind, randomized, placebo-controlled trial of intravenous (IV) N-acetylcysteine (NAC) vs. placebo for the treatment of non-acetaminophen ALF. The purpose of this study is to examine the safety and efficacy of intravenous NAC in children with ALF for whom no antidote or other specific treatment is available. Inclusion in the NAC Study required enrollment in the Pediatric Acute Liver Failure (PALF) Study Registry.

Primary Outcome

Spontaneous survival without transplant plus survival following transplantation

Interventions

  • DRUG Placebo
  • DRUG N-acetylcysteine

Trial Details

FieldValue
Enrollment Target 184 participants
Start Date 2000-01
Est. Completion 2010-10
Phase Phase 3
University of Pittsburgh

1,238 total trials

What the finished NCT00248625 record still lists

NCT00248625 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00248625 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00248625 about?

NCT00248625 is a clinical study titled "N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure". We have completed patient enrollment in the the double blind, randomized, placebo-controlled trial of intravenous (IV) N-acetylcysteine (NAC) vs. placebo for the treatment of non-acetaminophen ALF. The purpose of this study is to examine the safety and efficacy of intravenous NAC in children with AL...

What is the current status of trial NCT00248625?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 184 participants. The study started on 2000-01. Estimated completion is 2010-10.

What interventions are being tested in trial NCT00248625?

The interventions under investigation include: Placebo (DRUG), N-acetylcysteine (DRUG).

Who is sponsoring clinical trial NCT00248625?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00248625's enrollment target sits among peer trials

184 1418th of 2000 higher than 581 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03903510 · 184 participants · NA

    Virtual Reality During Pediatric Cast Removal

  • NCT04020510 · 184 participants · Phase 4

    Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder

  • NCT04135846 · 184 participants · Phase 2

    Alpha-1 Blockade for Alcohol Use Disorder (AUD)

  • NCT04396873 · 184 participants · Phase 1

    PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00248625, the US trial registry maintained by the National Library of Medicine. NCT00248625 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.